Vertex presents new data on benefits of Alyftrek
US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX) has announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and, in particular, its Alyftrek (vanzacaftor/tezacaftor/deutivacaftor).
The cystic fibrosis drug is approved in the USA and UK and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. It generated first-quarter 2025 sales of $54 million, way behind Vertex’ leading CF therapy Trikafta (elexacaftor/tezacaftor/ivacaftor), which recorded 42.54 billion revenues in the sae period.
These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze